Possible roles of short-chain fatty acids in the pathophysiology and treatment of irritable bowel syndrome

doi:10.5528/wjtm.122740

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 3

This Article

(4)

(3)

(0)

(31)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Translational Medicine

ISSN

2220-6132

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Transl Med. Sep 28, 2026; 12(3): 122740
Published online Sep 28, 2026. doi: 10.5528/wjtm.122740

Possible roles of short-chain fatty acids in the pathophysiology and treatment of irritable bowel syndrome

Magdy El-Salhy, Cheol Min Shin, Yong Sung Kim, Jan Gunnar Hatlebakk

Magdy El-Salhy, Jan Gunnar Hatlebakk, Department of Medicine, University of Bergen, Haukeland University Hospital, Bergen 5009, Norway

Cheol Min Shin, Internal Medicine, Seoul National University Bundang Hospital, Seongnam 13620, South Korea

Yong Sung Kim, Kim's GutEase Internal Medicine, Gunpo 15865, South Korea

Yong Sung Kim, Digestive Disease Research Institute, Wonkwang University School of Medicine, Iksan 54538, South Korea

Author contributions: El-Salhy M wrote the first draft of the manuscript; Shin CM, Kim YS, and Hatlebakk JG contributed to the data analyses and interpretation, and critically revised the manuscript for important intellectual content.

AI contribution statement: The article did not utilize any AI collaborative tools.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Magdy El-Salhy, Chief Physician, Professor Emeritus, Department of Medicine, University of Bergen, Haukeland University Hospital, Bergen 5009, Norway. magdy.el-salhy@helse-bergen.no

Received: April 27, 2026
Revised: June 16, 2026
Accepted: August 10, 2026
Published online: September 28, 2026
Processing time: 130 Days and 10.2 Hours

Core Tip

Core Tip: Butyric acid appears to play a significant role in irritable bowel syndrome (IBS) symptom manifestation and the overlapping chronic fatigue. Sodium butyrate in capsule form seems to be a promising treatment for IBS.